Skip to main content

Table 4 Best overall tumor response

From: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

Tumor Response as per RECIST v1.1 Arm A, N = 3 Arm B, N = 5
Number of patients Number of patients
CR 0 0
PR 0 0
SD 1 2
PD 2 3
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease as per RECIST 1.1